EWP
CRL icon

Elevation Wealth Partners’s Charles River Laboratories CRL Stock Holding History

Elevation Wealth Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.16K Sell
36
-3
-8% -$534 ﹤0.01% 878
2026
Q1 		$6.73K Buy
39
+15
+63% +$2.78K ﹤0.01% 611
2025
Q4 		$4.79K Buy
24
+3
+14% +$544 ﹤0.01% 641
2025
Q3 		$3.29K Buy
+21
New +$3.33K ﹤0.01% 551
2024
Q3 		– Sell
-9
Closed -$1.86K – 498
2024
Q2 		$1.86K Buy
+9
New +$2.04K ﹤0.01% 452

Other funds holding CRL

CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
LKIM
Lawson Kroeker Investment Management Omaha, Nebraska $361M AUM 22.26% 1-Year Est. Return

Elevation Wealth Partners's CRL Position: Q2 2026 in Review

Elevation Wealth Partners reduced its Charles River Laboratories (CRL) stake by 7.7% in Q2 2026, selling an estimated $534 and leaving 36 shares worth $8.16K. The position accounts for ﹤0.01% of the portfolio, ranked #878.

Elevation Wealth Partners first reported a position in CRL in Q2 2024 and has held it in 5 quarters since. 159 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Elevation Wealth Partners held 36 shares of Charles River Laboratories worth $8.16K as of Q2 2026.
  • Elevation Wealth Partners sold 3 Charles River Laboratories shares in Q2 2026, an estimated $534.
  • Charles River Laboratories made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #878 holding.
  • Elevation Wealth Partners first reported a position in Charles River Laboratories in Q2 2024 and has held it in 5 quarters since.
  • 159 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.